AVLN — Q2 2026 Financial Report Analysis

Overview

Avalyn Pharma, a Boston drug developer working on inhaled versions of the two existing pill treatments for pulmonary fibrosis (a scarring disease that steadily stiffens the lungs), lost $28.9 million in the second quarter of 2026, up from $20.2 million a year earlier. Avalyn has no products on the market and no revenue, so the loss is simply what it spent running clinical trials, less interest earned on its cash. The quarter's real news sits on the balance sheet: its May 1 initial public offering (IPO, its first sale of shares to the public) raised about $316.6 million after fees. That left $413.5 million in cash and short-term investments at June 30, which management says pays for operations "into 2029", well past the 2027 trial results the company is built around.

This is Avalyn's second quarterly report as a listed company. Its Nasdaq listing came in the middle of the quarter, so some per-share comparisons with last year don't hold (see below).

At a glance

• $413.5 million in cash and investments, up from $138.4 million at the end of 2025. Most of the jump is the IPO; at the first half's spending pace this covers more than three years.
• R&D spending of $24.7 million, up 38%. R&D (research and development, mainly paying for clinical trials) rose because its second drug, AP02, is now in a Phase 2 trial. AP02's direct costs were 3.6 times last year's.
• MIST, the trial that will decide the company's value, is fully enrolled. 398 patients joined, more than the 375 targeted. Results are due in the second half of 2027.

The numbers

Quarterly operating cash burn is our own subtraction: $56.0 million of net cash used in operating activities for the first half, minus $29.9 million for the first quarter. Because Avalyn has no revenue there is no operating margin to report. The usual yardsticks for a company at this stage are how fast it spends and how long its cash lasts.

Where the money went

Avalyn reports R&D by drug program, which shows clearly where the growth in spending came from:

• AP01 is still the biggest cost at 55% of R&D. The filing ties its $1.1 million increase to "the progression of the Phase 2b clinical trial and ongoing OLE trial". The OLE (open-label extension) is SAIL, where patients from earlier studies keep taking the drug. AP01's costs grew only 9%, which fits a trial that has finished signing up patients and is now mostly following them.
• AP02 is the fastest-growing cost. Its $3.6 million increase came from its Phase 2 trial, AURA, which started enrolling in the first quarter of 2026. For the first half, AP02's direct costs were $9.7 million against $2.1 million a year earlier.
• G&A rose 68% to $6.6 million. G&A (general and administrative, i.e. overhead) grew through $1.4 million more in staff costs including stock compensation, $0.8 million more in legal and consulting fees "to support public company operations", and $0.5 million more in rent from an office sublease signed in September 2025. Being a listed company costs money every year, so this level is likely to stay.

The pipeline

Avalyn's strategy is to take the two antifibrotic drugs doctors already prescribe as pills, pirfenidone and nintedanib, and deliver them by nebulizer straight into the lungs. The goal is a higher dose where the disease is, with fewer of the stomach, liver and skin side effects that lead many patients to stop or never start the pills. The filing's risk section notes that the market today relies on three oral drugs: nintedanib, pirfenidone and nerandomilast.

• AP01 / MIST (Phase 2b, progressive pulmonary fibrosis): a 52-week placebo-controlled trial of two doses. The main measure is the change in forced vital capacity (FVC), meaning how much air a patient can forcefully breathe out, the standard measure of whether fibrosis is getting worse. Enrollment finished at 398 patients, and topline data are expected in the second half of 2027. AP01 has had FDA orphan drug designation for IPF since 2014, which brings extra market exclusivity if it is approved.
• AP02 / AURA (Phase 2, idiopathic pulmonary fibrosis, or IPF): a 12-week trial of two doses, planned for 160 patients. The company says enrollment is "on track" and data are expected in late 2027.
• AP03 (inhaled pirfenidone plus nintedanib in one product): a Phase 1 study is planned to start by the end of 2026.

After the quarter ended, Avalyn added Robert Meyer, M.D. to its board on September 15, 2026 (8-K filed September 16). He ran the FDA's Division of Pulmonary and Allergy Drug Products from 1999 to 2002 and later its Office of Drug Evaluation II. For a company heading toward regulatory decisions on lung drugs, that is relevant experience.

What the headline numbers hide

• The drop in loss per share is mostly an accounting effect. The loss per share fell from $17.63 to $0.98 while the dollar loss rose 43%. Before the IPO, almost all of Avalyn's ownership was preferred stock, which is left out of the share count used for this calculation. Only about 1.1 million common shares (weighted average) counted in Q2 2025, against 29.7 million in Q2 2026, after the preferred shares converted and IPO shares were added on May 1. As of August 10, 2026 there were 44.3 million shares outstanding. On our arithmetic, a Q2-sized loss spread over that count would be roughly $0.65 a share in Q3. A smaller per-share figure there would also come from the share count, not from lower spending.
• Cash burn is close to the reported loss. Operating cash burn was about $26.1 million in Q2 against the $28.9 million loss. The main difference is $2.8 million of stock-based compensation, which is a real cost to shareholders because it dilutes them, but not a cash payment. Stock compensation was $1.1 million a year earlier, so non-cash pay is growing faster than the business. In the first half, Avalyn also used $4.1 million of cash to cut accrued liabilities (from $9.9 million to $7.3 million) and accounts payable, so it was paying down bills rather than delaying them.
• Interest income is propping up the loss. Interest income was $2.7 million in Q2, against $1.6 million a year earlier. Without it, the net loss would have been about $31.6 million. The filing says the increase came from the IPO cash, "partially offset by the impact of lower federal funds rates". If rates keep falling, this support shrinks.
• Some of the cash is borrowed. In February 2026, Avalyn drew $15.0 million of a $30.0 million term loan from Banc of California. The rate is the higher of the prime rate or 5.00%, the loan matures June 30, 2030, and the other $15.0 million can be drawn through December 31, 2027. Net of that debt, cash is about $398.5 million. The loan is small next to the cash pile, but its covenants restrict how the company can operate, as the risk factors point out.
• The runway guidance looks conservative. First-half operating cash burn was $56.0 million, or about $112 million a year. At that rate, $413.5 million would last about 3.7 years from June 30, which is into early 2030. Management's "into 2029" suggests it expects spending to rise, which fits planning later-stage trials and the AP03 Phase 1. Either way, the cash covers both 2027 data readouts with a year or more to spare. That matters, because companies that must raise money just before a binary result usually do it on worse terms.
• No one-off items distort either year. The quarter is clean apart from the share count change. There is no revenue, no impairment and no restructuring charge.

Takeaway: The $316.6 million IPO changed Avalyn's position more than any operating figure did: it now has about $413.5 million, which covers both of its 2027 readouts (MIST for AP01 and AURA for AP02) with runway to spare. Until then, the quarterly loss mostly reflects how quickly those trials progress. The company's value depends on whether MIST shows inhaled pirfenidone slows lung-function decline with fewer side effects than the pill.

Outlook

Management did not give expense guidance beyond the cash runway "into 2029". Dated milestones from the filing and the August 12 earnings release:

Our read: expect quarterly losses to keep rising for now. AURA is still enrolling, AP03 is moving into the clinic, and public-company overhead is now a fixed cost. A Q2-sized run rate means roughly $110–120 million of operating cash burn a year. Between now and the end of 2027, news will mostly be operational: AURA enrollment progress, the AP03 Phase 1 start, and SAIL extension data. The ex-FDA pulmonary-division head on the board is a sensible addition before regulatory talks. The main risk is concentration. AP01 and AP02 use the same idea, so a MIST result that fails to show a lung-function benefit over placebo would hurt confidence in the whole platform, not just one drug. For the next 10-Q, watch whether AP02 costs keep climbing as AURA fills up and whether the runway guidance stays at "into 2029".